Contract with Customer, Liability, Current of ELITE PHARMACEUTICALS INC /NV/ from 31 Mar 2021 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly Contract with Customer, Liability, Current in USD history and change rate from 31 Mar 2021 to 30 Jun 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Contract with Customer, Liability, Current for the quarter ending 30 Jun 2025 was $2,222, a 83% decline year-over-year.
Source SEC data
View on sec.gov
Contract with Customer, Liability, Current, Quarterly (USD)
Contract with Customer, Liability, Current, YoY Quarterly Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Contract with Customer, Liability, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $2,222 -$11,111 -83% 30 Jun 2025 10-Q 14 Aug 2025 2026 Q1
Q1 2025 $5,556 -$7,777 -58% 31 Mar 2025 10-Q 17 Feb 2026 2026 Q3
Q4 2024 $8,889 -$4,444 -33% 31 Dec 2024 10-Q 13 Feb 2025 2025 Q3
Q3 2024 $12,222 -$1,111 -8.3% 30 Sep 2024 10-Q 14 Nov 2024 2025 Q2
Q2 2024 $13,333 $0 0% 30 Jun 2024 10-Q 14 Aug 2024 2025 Q1
Q1 2024 $13,333 $0 0% 31 Mar 2024 10-K 30 Jun 2025 2025 FY
Q4 2023 $13,333 $0 0% 31 Dec 2023 10-Q 14 Feb 2024 2024 Q3
Q3 2023 $13,333 $0 0% 30 Sep 2023 10-Q 14 Nov 2023 2024 Q2
Q2 2023 $13,333 $0 0% 30 Jun 2023 10-Q 14 Aug 2023 2024 Q1
Q1 2023 $13,333 $0 0% 31 Mar 2023 10-K 01 Jul 2024 2024 FY
Q4 2022 $13,333 $0 0% 31 Dec 2022 10-Q 14 Feb 2023 2023 Q3
Q3 2022 $13,333 30 Sep 2022 10-Q 14 Nov 2022 2023 Q2
Q2 2022 $13,333 30 Jun 2022 10-Q 15 Aug 2022 2023 Q1
Q1 2022 $13,333 $0 0% 31 Mar 2022 10-K 29 Jun 2023 2023 FY
Q4 2021 $13,333 31 Dec 2021 10-Q 14 Feb 2022 2022 Q3
Q1 2021 $13,333 31 Mar 2021 10-K 29 Jun 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.